Skip to main content
Premium Trial:

Request an Annual Quote

NEC to Market SomaLogic's Proteomic Assay in Japan

NEW YORK (GenomeWeb) – SomaLogic and NEC today announced an exclusive deal granting NEC exclusive marketing rights to the Somascan assay in Japan.

NEC will market the assay to biopharmaceutical firms, food companies, and academic research centers in the country. The assay leverages SomaLogic's Somamer technology to identify and quantify 1,129 proteins across a wide range of concentrations in small volumes of various biological samples.

The agreement expands a 2010 deal between SomaLogic and NEC to investigate applications for SomaLogic's technology in the life sciences and healthcare markets. Under the earlier deal, NEC developed the Somasuite software tool for interpreting large datasets produced by the Somascan assay. The software will be provided to Somascan assay clients under the new agreement, the partners said.

Financial and other terms of the agreement were not disclosed.